Cabozantinib for the treatment of non-small cell lung cancer with KIF5B-RET fusion. An example of swift repositioning.
about
A Receptor Tyrosine Kinase Inhibitor, Dovitinib (TKI-258), Enhances BMP-2-Induced Osteoblast Differentiation In Vitro.Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma.Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathwayAn overview of quinoline as a privileged scaffold in cancer drug discovery.(-)-Guaiol regulates RAD51 stability via autophagy to induce cell apoptosis in non-small cell lung cancer.A novel multi-target inhibitor harboring selectivity of inhibiting EGFR T790M sparing wild-type EGFR.
P2860
Cabozantinib for the treatment of non-small cell lung cancer with KIF5B-RET fusion. An example of swift repositioning.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Cabozantinib for the treatment ...... xample of swift repositioning.
@en
type
label
Cabozantinib for the treatment ...... xample of swift repositioning.
@en
prefLabel
Cabozantinib for the treatment ...... xample of swift repositioning.
@en
P2093
P2860
P1476
Cabozantinib for the treatment ...... xample of swift repositioning.
@en
P2093
Minsoo Song
Seong-Heon Kim
Suk Kyoon Yoon
P2860
P2888
P304
P356
10.1007/S12272-015-0660-1
P577
2015-09-16T00:00:00Z
P6179
1042429549